The new technology from University of Houston could make any mask more resistant to viruses. Photo courtesy of Seamus Curran/Integricote

The start of 2020, though most didn't know it at the time, meant a huge change to society. Though coronavirus didn't yet seem to be an issue for the United States, the world was entering into a new normal where wearing face masks in public is common and necessary to prevent the spread of COVID-19.

"We left normal in December," says Seamus Curran, a professor of physics at the University of Houston, "and, when everyone was planning their New Year's resolutions, little did we know that the old normal of before is gone. None of us saw that life passing away — and it was taken away by a bug 1,000 times smaller than lice. And like lice, it's going to be with us for a long time."

To that end, Curran, who is well-known for his work commercializing nanotechnologies, is pulling from his past to deal with a future demand. The professor is using a hydrophobic coating he developed nearly 10 years ago to improve the ability of surgical masks to protect against transmission of the virus.

It's no secret that good face masks are a dire, worldwide need. But Curran notes that standard masks are "somewhat porous, and especially if they get wet, they can allow the virus to penetrate." People infected with the virus, he adds, could spread it even through a mask, while people who aren't sick could still become infected, despite wearing a less-protective mask.

Curran calls N95 masks, "the gold standard, able to filter very small particles and offering better protection than standard surgical masks." But he notes that they are hard to manufacture, and global demand is for tens of millions of items. His work will make masks impervious to water, thus improving protection, he explains.

That means those who already own masks are in luck: Curran's team is planning to sell spray for the hydrophobic coatings so that people can apply it themselves at home or at work. "However, it's cheaper and far more effective to be able to apply it in large batch quantities that manufacturers can do," Curran adds.

The globally minded Curran has only one local requirement: "We will only sell to U.S. manufacturers that manufacture here in the U.S. It's not a limiting factor and may change in the future, but right now, I have to deal with my community here in Houston, Texas, and the U.S. It has to be my priority."

University of Houston's Dr. Seamus Curran. Photo courtesy of University of Houston

Curran and his team are working though the process to make sure their coatings are compliant with all federal rules. "Sometimes, this is making sure your materials are registered and allowed," he says. "Sometimes it's making sure the products follow relevant EPA and FDA guidelines. However, we are very close, as in weeks, and not some arbitrary academic timeline in the distant future."

He first launched a nanotechnology business in 2013, according to UH. His company, Integricote, based at the UH Technology Bridge, focuses on manufacturing sealers for masonry, wood, and concrete. The professor has developed nanotech coatings for fabrics since 2011, technology that he now is using to demonstrate a way to provide more protection against SARS and COVID-19.

Curran, who often says he hates to "play defense," hopes to get a jump on the virus spread with his new technology and take a proactive approach to a long-term issue. "Remember, H1N1 affected 61 million Americans and 12,500 people died from it between 2009 and 2010," he notes. "Do we think that's it? Did we think Ike was the last big hurricane to hit us, or do we expect more? Yet, we have compensated for this and found a way to be resilient and have a normal life."

Technical and scientific in his work, the passionate professor says he is galvanized by a simple, primal motive. "This is personal, this virus has threatened my family and I'm not sitting back, ideally, just letting this happen," Curran says. "I'm just like any other husband, father, son, brother, and uncle: I will do all I can to protect those dearest to me and I will not have it any other way."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”